By Maggie Fick LONDON, June 8 (Reuters) - AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 ...

AstraZeneca’s experimental GLP-1 pill cut body weight by nearly 12% in obese patients over 36 weeks and reduced A1C, a metric ...

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other ...

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight ...

AstraZeneca announced on Friday an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth ...

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer ...

AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

The approval relies on positive data from the POTOMAC Phase III trial.

How decision velocity closes the gap between insight and action in complex, fast-moving supply chains ANTWERPEN, BE / ACCESS Newswire / May 7, 2026 / OMP, a leader in AI-powered supply chain planning, ...

An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...